Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotechnology company focusing on therapies for kidney disease, announced its participation in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference.

Dr. Shalabh Gupta, CEO, will represent Unicycive at the virtual event on May 30, 2024, at 9:30 a.m. ET. The live and archived webcast will be accessible on the Unicycive website under the Investors section for three months.

Positive

• Participation in the Lytham Partners Spring 2024 Investor Conference may enhance investor visibility and interest.
• The CEO’s involvement adds credibility and may positively impact investor sentiment.

Negative

• The announcement lacks specific financial or clinical updates, which may leave investors wanting more substantial information.
• Participation in an investor conference does not guarantee any immediate financial benefits or stock price increase.

LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a Fireside Chat at the virtual Lytham Partners Spring 2024 Investor Conference on Thursday, May 30, 2024, at 9:30 a.m. ET.

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.

Investor Contact:

ir@unicycive.com
(650) 543-5470

SOURCE: Unicycive Therapeutics, Inc.

FAQ

When is Unicycive Therapeutics participating in the Lytham Partners Spring 2024 Investor Conference?

Unicycive Therapeutics will participate on May 30, 2024, at 9:30 a.m. ET.

How can I access the Unicycive Therapeutics Fireside Chat webcast?

The webcast can be accessed live and in archive on the Unicycive website under the Investors section: Events and Presentations.

How long will the archived webcast of the Unicycive Therapeutics Fireside Chat be available?

The archived webcast will be available for three months.